‍

genOway’s program at the American Association for Cancer Research Annual Meeting 2026

‍

Watch the recap of our presence at the AACR here:

🔬 Spotlight Theater presentation

‍

Tuesday, April 21, 2026 | 10 am - Spotlight Theater D

Title: "Enhancing the Translatability of Biologic’s Immune Related Effects and Efficacy Using One Humanized Mouse Model"

• genO-BRGSF-HIS mice recapitulate key CRS features induced by biologics tested in the clinic
• Immune cells are recruited, polarized and activated in the tumor microenvironment in genO-BRGSF-HIS mice
• genO-BRGSF-HIS enables the assessment of both efficacy and safety in a single model

Presenter: Kader Thiam, CSO & SVP – Discovery, Preclinical Models & Services

‍

This Exhibitor Spotlight Theater is a promotional activity and is not approved for continuing education credit. The content of this Exhibitor Spotlight Theater are the opinions of the presenter and do not represent the position or the opinion of the American Association for Cancer Research® (AACR) or its members.

‍

📰 Join us for our poster presentations!

‍

Monday April 20, 2026, 9:00 am

• Poster 1601, title: A novel preclinical tool to unlock the potential of IL-18 in cancer immunotherapy: genO-hIL-18/hIL-18R mice
  
  • Humanization of both IL-18 and IL-18R is required for a functional axis and does not alter immune cell distribution in genO-hIL-18/hIL-18R compared to WT mice
  • Human IL-18 secretion can be induced in vivo in genO-hIL-18/hIL-18R model
  • genO-hIL-18/hIL-18R model is suitable to assess new therapies targeting the IL-18/IL-18 axis

• Poster 2168, title: Human IgG1-expressing mouse models for tolerance induction and reliable assessment of IgG1-based therapeutic antibodies
  
  • genO-hIgG1 models display intact Ig class switch
  • Humanization of IgG1 in genO-hSA/hFcRn model induces tolerance to human IgG1-based therapies
  • IgG1 humanization in genOway syngeneic models enhances clinical translatability through mitigation of ADA development

Monday April 20, 2026, 2:00-5:00 pm

• Poster 3371, title: genO-BRGSF-HIS mice: A humanized mouse model for assessment of Treg-targeting therapies
  
  • T cell subsets develop in genO-BRGSF-HIS mice, including γδT cells and Tregs
  • genO-BRGSF-HIS exhibits a human-like CCR8 pattern of expression and is suitable to assess efficacy of Treg-depleting therapies
  • genO-BRGSF-HIS model supports tumor engraftment and enables characterization of activated Treg subsets infiltrating the TME

Tuesday April 21, 2026, 2:00-5:00 pm

• Poster 6699, title: Novel preclinical immunocompetent mouse model for assessment of immunotherapies targeting cGAS-STING axis
  
  • Humanization of cGAS and STING does not alter immune cell distribution in genO-hcGAS, genO-hSTING and genO-hcGAS/hSTING models
  • Human cGAS and STING expressed in genO-hcGAS/hSTING mice are functional, as demonstrated by downstream signaling and cytokine release upon stimulation with human-specific agonists
  • Efficacy and specificity of compounds targeting the human cGAS/STING pathway can be assessed in genO-hcGAS, genO-hSTING and genO-hcGAS/hSTING models

• Poster 6072, title: Characterization of the immunological responses in a mouse model expressing humanized FcγR/FcRn
  
  • Humanization of Fcγ receptors and FcRn does not alter immune cell distribution in genO-hFcγR/hFcRn model
  • genO-hFcγR/hFcRn model exhibits immune responses comparable to WT following defined immunological challenges
  • genO-hFcγR/hFcRn model is suitable for studying Fc-engineered therapeutic antibodies in a physiologically relevant immune context

‍

Not affiliated with or endorsed by AACR.